Elevance Health, Inc. (NYSE:ELV) is highlighted as one of the Most Undervalued Long Term Stocks to Buy Right Now, with a Buy rating and $400 price target from Cantor Fitzgerald. The firm maintains a cautious outlook on the 2026 Medicaid Environment, emphasizing the importance of execution in key segments for the company’s success in 2026 and 2027. Despite the cautious outlook, Cantor Fitzgerald believes ELV will outperform expectations in Medicare Advantage and Carelon. ELV is a US-based health insurer offering various health plans and services. While ELV shows potential as an investment, some AI stocks may offer greater upside potential with lower downside risk. For more information on short-term AI stock opportunities, check out the free report linked in the article.

Read more at Yahoo Finance: Cantor Fitzgerald Reiterates a Buy Rating on Elevance Health (ELV), Keeps the PT